Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma

doi:10.12998/wjcc.v10.i11.3321

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5214)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

302

WORD

HTML

2718

Figures (1-1)

252

Tables (1-2)

215

Sum=3581

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

231

Download

389

Sum=620

Publishing Process of This Article

Item

Count

Browse

238

Download

775

Sum=1013

Apr 16, 2022 (publication date) through Jul 29, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Cases. Apr 16, 2022; 10(11): 3321-3333
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3321

Full Size Figure Download Figure

Figure 1 Some signals in the Wnt/β-catenin pathway by anti-signaling antibodies or intervening in their gene transcription to inhibit hepatocellular carcinoma growth. Using anti-signaling molecule antibodies or intervening in their gene transcription to inhibit Wnt/β-catenin pathway activation could suppress proliferation of hepatocellular carcinoma (HCC) cells or HCC growth. GPC-3: Glypican-3; HCC: Hepatocellular carcinoma; sCLU: Secretory clusterin; TCF: T-cell factor; SULF2: Sulfatase 2; pGSK3β: Phosphorylated glycogen synthase kinase 3β.

Citation: Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333
URL: https://www.wjgnet.com/2307-8960/full/v10/i11/3321.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i11.3321